European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva
- ByBenzinga-
RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted...